Former J&T Executive Takes Helm at Struggling Slovak Pharma Firm Biotika

Biotika, a Slovak pharmaceutical company in serious financial difficulty, is attempting a turnaround under new leadership drawn from the prominent Central European financial and investment group J&T. The company, which has suffered significant losses running into the millions of euros, is now searching for new markets to stabilize its operations — including potential expansion into China. Biotika, based in Slovakia, produces pharmaceutical and biological products but has faced mounting financial pressure in recent years. The appointment of a former J&T manager signals an effort to bring in experienced corporate leadership to restructure the ailing firm. J&T is one of the largest and most influential private investment groups in Central and Eastern Europe, with interests spanning banking, real estate, energy, and healthcare. Despite the leadership change, Biotika has not been able to avoid recording a multi-million euro loss in its most recent financial period. The company's strategy for recovery includes diversifying into new international markets, with China identified as one potential growth area. Whether the turnaround effort will be sufficient to restore the company to profitability remains to be seen.